Ok. We've been debating for a while now whether to use the International Proprietary Name (INN) or a distinct new name for biosimilars. Not surprisngly, the innovator companies (pharma and biotechs) want to see a new name distinct from that of the originator drug. The biosimilar producers want the INN. This appears to be about either erecting a further hurdle to substitution by requiring a unique name or making that process easier which is predicted to speed adoption of biosimilars in the US.
Now we have a coalition of 32 major pharmacies (Walgreens, National Assn of Chain Drugs groups), health insurers (CVS Caremark and Express Scripts), unions (AFL-CIO and AFSCME), pension plans (CaLPERS) and the American Health Insurance Plans trade association asking FDA to use the INN. Their clear objective in askng is to speed adoption and save costs to the whole healthcare system. So that's the latest salvo in this burgeoning battle. See Pharmalot in WSJ.
Posted by Bruce Lehr July 2nd 2014.